ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,353.76
0.00%
Dow Jones
39,056.39
0.44%
Gold vs US Dollar
2,308.645
0.02%
Brent Oil
83.995
0.52%
Bitcoin
60,970.28
-0.35%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Oaktree Acquisition Corp II (OACB)

  7. Oaktree Acquisition Corp II (OACB) News

Oaktree Acquisition Corp... (OACB)

Oaktree Acquisition Corp II
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:OACB
DateTimeSourceHeadlineSymbolCompany
15/06/202216:36Edgar (US Regulatory)Notification Filed by a National Securities Exchange to Report the Removal From Listing and Registration of Matured , Redeemed or Retired Securities (25)NYSE:OACBOaktree Acquisition Corp II
09/06/202212:10Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NYSE:OACBOaktree Acquisition Corp II
09/06/202202:16Business WireAlvotech und Oaktree Acquisition Corp. II melden Zustimmung der Aktionäre zum UnternehmenszusammenschlussNYSE:OACBOaktree Acquisition Corp II
08/06/202210:54Business WireAlvotech et Oaktree Acquisition Corp. II annoncent l'approbation des actionnaires pour le regroupement d'entreprisesNYSE:OACBOaktree Acquisition Corp II
07/06/202221:00Business WireAlvotech and Oaktree Acquisition Corp. II Announce Shareholder Approval of Business CombinationNYSE:OACBOaktree Acquisition Corp II
03/06/202222:29Edgar (US Regulatory)Current Report Filing (8-k)NYSE:OACBOaktree Acquisition Corp II
03/06/202222:17Business WireOaktree Acquisition Corp. II Announces Delisting of its Securities Effective and Conditional Upon Consummation of its Pending Business Combination with AlvotechNYSE:OACBOaktree Acquisition Corp II
31/05/202222:19Edgar (US Regulatory)Current Report Filing (8-k)NYSE:OACBOaktree Acquisition Corp II
24/05/202212:24Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NYSE:OACBOaktree Acquisition Corp II
24/05/202212:00Business WireAlvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT04 and Reference Product Stelara®NYSE:OACBOaktree Acquisition Corp II
17/05/202214:00Edgar (US Regulatory)Current Report Filing (8-k)NYSE:OACBOaktree Acquisition Corp II
16/05/202220:08Edgar (US Regulatory)Quarterly Report (10-q)NYSE:OACBOaktree Acquisition Corp II
16/05/202213:07Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NYSE:OACBOaktree Acquisition Corp II
16/05/202213:00Business WireAlvotech Announces Positive Results from a Pharmacokinetic Similarity Study for AVT04, a Proposed Biosimilar to Stelara®NYSE:OACBOaktree Acquisition Corp II
11/05/202213:00Business WireAlvotech, Global Biotech Company, and Oaktree Acquisition Corp. II Announce June 7, 2022 Extraordinary General Meeting to Approve Business CombinationNYSE:OACBOaktree Acquisition Corp II
10/05/202223:34Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NYSE:OACBOaktree Acquisition Corp II
22/04/202221:31Edgar (US Regulatory)Current Report Filing (8-k)NYSE:OACBOaktree Acquisition Corp II
20/04/202222:00Business WireAlvotech améliore son accès aux capitaux et optimise son processus d’entrée en bourse, prévue sur le NASDAQNYSE:OACBOaktree Acquisition Corp II
20/04/202217:45Business WireAlvotech verbessert Zugang zu Kapital und ebnet Weg für erwartete NASDAQ-NotierungNYSE:OACBOaktree Acquisition Corp II
20/04/202213:15Business WireAlvotech migliora l'accesso al capitale e semplifica il percorso verso la prevista quotazione in Borsa al NASDAQNYSE:OACBOaktree Acquisition Corp II
19/04/202223:00Business WireAlvotech Improves Access to Capital and Streamlines Path to Expected Public Listing on NASDAQ Stock ExchangeNYSE:OACBOaktree Acquisition Corp II
19/04/202222:26Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NYSE:OACBOaktree Acquisition Corp II
18/04/202222:12Edgar (US Regulatory)Current Report Filing (8-k)NYSE:OACBOaktree Acquisition Corp II
08/04/202215:01Business WireアルヴォテックとSTADA、アッヴィとの欧州特許紛争を解決してHumira®のクエン酸フリー高濃度バイオシミラーHUKYNDRA®（AVT02）発売への道を開くNYSE:OACBOaktree Acquisition Corp II
07/04/202202:15Business WireAlvotech et STADA ouvrent la voie au lancement de HUKYNDRA® (AVT02), un biosimilaire de l'Humira® haute concentration sans citrate, en réglant le litige de brevet européen qui les opposait à AbbVieNYSE:OACBOaktree Acquisition Corp II
06/04/202223:21Business WireAlvotech und STADA ebnen durch Beilegung des europäischen Patentstreits mit AbbVie den Weg für die Markteinführung von HUKYNDRA®(AVT02), einem zitratfreien, hochkonzentrierten Biosimilar zu Humira®NYSE:OACBOaktree Acquisition Corp II
06/04/202212:51Edgar (US Regulatory)Current Report Filing (8-k)NYSE:OACBOaktree Acquisition Corp II
06/04/202212:00Business WireAlvotech and STADA Pave Way to Launching HUKYNDRA®(AVT02), a Citrate-free, High-concentration Biosimilar to Humira® by Resolving European Patent Dispute With AbbVieNYSE:OACBOaktree Acquisition Corp II
23/03/202220:20Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NYSE:OACBOaktree Acquisition Corp II
14/03/202211:10Business Wireアルヴォテックがアッヴィとの米国特許・企業秘密紛争を解決し、Humira®向けにアルヴォテックが提案中の高濃度バイオシミラー（AVT02）の米国での権利を確保NYSE:OACBOaktree Acquisition Corp II
 Showing the most relevant articles for your search:NYSE:OACB

Your Recent History

LSE
POS
Plexus
LSE
TERN
Tern
LSE
ITV
Itv
LSE
GOLD
LSE
BIRD
Blackbird
LSE
GWMO
Great Western Mining
LSE
SYME
Supply@me Capital
LSE
KEFI
Kefi Gold And Copper
LSE
SCE
Surface Transforms
LSE
PET
Petrel Resources
LSE
TYM
Tertiary Minerals
LSE
FDEV
Frontier Developments
LSE
LND
Landore Resources
LSE
DEC
Diversified Energy
LSE
AAU
Ariana Resources
LSE
VAST
Vast Resources
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved